These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 2649640)

  • 1. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
    Cedarbaum JM; Hoey M; McDowell FH
    J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):207-12. PubMed ID: 2649640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
    Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
    Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.
    Factor SA; Sanchez-Ramos JR; Weiner WJ; Ingenito AM
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):83-8. PubMed ID: 2709040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Oct; 37(10):1607-12. PubMed ID: 3658164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Ahlskog JE; Muenter MD; McManis PG; Bell GN; Bailey PA
    Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
    Lieberman A; Gopinathan G; Miller E; Neophytides A; Baumann G; Chin L
    Eur Neurol; 1990; 30(2):75-8. PubMed ID: 2340838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
    Jankovic J; Schwartz K; Vander Linden C
    Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
    Bulling MT; Wing LM; Burns RJ
    Aust N Z J Med; 1991 Aug; 21(4):397-400. PubMed ID: 1953526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
    Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
    Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
    Cedarbaum JM; Silvestri M; Clark M; Toy L; Harts A; Green-Parsons A; McDowell FH
    J Neural Transm Park Dis Dement Sect; 1990; 2(3):205-13. PubMed ID: 2257060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of Sinemet CR4 in patients with Parkinson's disease.
    Anderson TJ; Ewer TC; Gilchrist NL; Donaldson IM
    N Z Med J; 1992 Mar; 105(929):81-2. PubMed ID: 1545941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
    [No Abstract]   [Full Text] [Related]  

  • 17. Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.
    Ming A; Temlett JA; Fritz VU
    J Intern Med; 1991 Aug; 230(2):113-7. PubMed ID: 1865161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.
    Wolters EC; Tesselaar HJ
    J Neurol; 1996 Mar; 243(3):235-40. PubMed ID: 8936353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.